Results 71 to 80 of about 25,027 (259)
A new metabolic path in type 3 rickets
The FEBS Journal, EarlyView.Rickets, a bone disorder, was historically categorised into either nutritional (vitamin D deficiency) or genetic forms involving loss‐of‐function mutations in mineral metabolism. Recently, a new mechanism, type 3 rickets, was discovered to be caused by a gain‐of‐function mutation in CYP3A4 (Ile301Thr).
Toshiya Senda, Yoshihisa Hirota
wiley +1 more source
Journal of Periodontal Research, EarlyView.Effects of exogenous tissue‐nonspecific alkaline phosphatase (TNAP) were analyzed in the Hyp mouse model of X‐linked hypophosphatemia (XLH). Maxillary first molars were extracted from wild‐type (WT) and Hyp mice at 6 weeks, and collagen gel ± TNAP was placed in sockets. In one group of Hyp mice, submucosal injections of TNAP or saline were delivered at
Aonjittra Phanrungsuwan +3 more
wiley +1 more source
Treatable Leukoencephalopathy in a Patient with Hypophosphatemia
Case Reports in Neurology, 2017 We report the first patient with pathologically proven leukoencephalopathy associated with hypophosphatemia. A 61-year-old woman had repetitive episodes of decreased consciousness with pontine and pallidal lesions and extensive leukoencephalopathy on MRI,
Masahiro Okazaki +6 more
doaj +1 more source
Frontiers in Endocrinology, 2020 Burosumab (KRN23) is an FGF23 neutralizing antibody that has been the subject of several recent clinical trials principally focused on the treatment of hypophosphatemic rickets in patients with X-linked hypophosphatemia (XLH).
A. Schindeler, A. Biggin, C. Munns
semanticscholar +1 more source
Transfusion Medicine, EarlyView.Abstract Solid organ transplant is associated with high rates of anaemia and transfusion, but there is little comparative data on interventions such as erythropoietin‐stimulating agents (ESAs) and intravenous (IV) iron. We conducted a systematic review examining the association of ESAs and IV iron with outcomes in adults undergoing solid organ ...
Frank Lee +13 more
wiley +1 more source
Iron infusion in pregnancy and dental dysplasia in children—is there a link?
Frontiers in PediatricsSome intravenous iron preparations cause hypophosphatemia mediated by increased fibroblast growth factor 23. This hypophosphatemia lasts for weeks or months and, when administered to pregnant women, could affect fetal tooth mineralization, which starts ...
Gabriela Amstad, Tilo Burkhardt
doaj +1 more source
Fever as a cause of hypophosphatemia in patients with malaria. [PDF]
PLoS ONE, 2007 Hypophosphatemia occurs in 40 to 60% of patients with acute malaria, and in many other conditions associated with elevations of body temperature. To determine the prevalence and causes of hypophosphatemia in patients with malaria, we retrospectively ...
Warren Browner, Richard Haber
doaj +1 more source
Cancer Medicine, Volume 15, Issue 2, February 2026.ABSTRACT Introduction Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (
Dana Sofian Abou +6 more
wiley +1 more source
Gendered Experiences of Intravenous Iron Infusion Reactions: A Patient Perspective
Journal of Patient ExperienceHypophosphatemia following iron infusion is thought to be a relatively rare complication of intravenous iron infusion, though research is beginning to demonstrate that it occurs more often than previously assumed.
Roxanna Nasseri Pebdani PhD, CRC, SFHEA
doaj +1 more source
Respiratory failure in a diabetic ketoacidosis patient with severe hypophosphatemia [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2018 Phosphate is essential in regulating human metabolic processes, and severe hypophosphatemia can induce neurologic and hematological complications and result in respiratory failure and cardiac dysfunction.
Han Saem Choi +5 more
doaj +1 more source